IDSA 8x10 - 16pp+cover FINAL.indd - IDSA Foundation
IDSA 8x10 - 16pp+cover FINAL.indd - IDSA Foundation
TABLE OF CONTENTS MESSAGE FROM LEADERSHIP . 1 WAYS TO SUPPORT . 3 ONE KEY TO STOPPING EPIDEMICS IS TO RECOGNIZE “WHAT’S NEXT.”: DR. DANIEL LUCEY . 4 THE IDSA FOUNDATION’S IMPACT . 7 THE TOP 9 INFECTIOUS DISEASES OUTBREAKS OF 2018 . 8 TRUE PIONEERS IN RESEARCH: DR. & MRS. LESLIE AND RAINEY NORINS . 10 FINANCIAL INFORMATION . 13 2018 DONORS . 14 BOARD OF DIRECTORS AND STAFF . 16 . 8 7 2018 DONORS BOARD OF DIRECTORS AND STAFF FINANCIAL INFORMATION 2018 DONORS BOARD OF DIRECTORS AND STAFF TRUE PIONEERS IN RESEARCH: DR. & MRS. LESLIE AND RAINEY NORINS FINANCIAL INFORMATION BOARD OF DIRECTORS AND STAFF WAYS TO SUPPORT ONE KEY TO STOPPING EPIDEMICS IS TO RECOGNIZE “WHAT’S NEXT.”: DR.
DANIEL LUCEY .
. . 10 THE TOP 9 INFECTIOUS DISEASES OUTBREAKS OF 2018 TRUE PIONEERS IN RESEARCH: DR. & MRS. LESLIE AND RAINEY NORINS FINANCIAL INFORMATION . 13 . BOARD OF DIRECTORS AND STAFF . MESSAGE FROM LEADERSHIP TABLE OF CONTENTS MESSAGE FROM LEADERSHIP . ONE KEY TO STOPPING EPIDEMICS IS TO TABLE OF CONTENTS MESSAGE FROM LEADERSHIP . . 3 THE IDSA FOUNDATION’S IMPACT THE TOP 9 INFECTIOUS DISEASES OUTBREAKS OF 2018 TRUE PIONEERS IN RESEARCH: DR. & MRS. LESLIE AND RAINEY NORINS . . . WAYS TO SUPPORT ONE KEY TO STOPPING EPIDEMICS IS TO RECOGNIZE “WHAT’S NEXT.”: DR. DANIEL LUCEY THE IDSA FOUNDATION’S IMPACT THE TOP 9 INFECTIOUS DISEASES .
. . . 16 . RECOGNIZE “WHAT’S NEXT.”: DR. DANIEL LUCEY THE IDSA FOUNDATION’S IMPACT THE TOP 9 INFECTIOUS DISEASES . DR. & MRS. LESLIE AND RAINEY NORINS . . . . 1 INFECTIOUS DISEASES SOCIETY OF AMERICA FOUNDATION
1 Dear IDSA Foundation Supporters, Your IDSA Foundation is hard at work to becoming the nation’s premier resource for Building the Future of Infectious Diseases. This year, the IDSA Foundation shined a light on the power of mentorship, and the incredible leaders in the ﬁeld who have helped cultivate the ID Detectives of today – and tomorrow. The IDSA Foundation knows the next generation of ID Detectives will become the drivers of scientiﬁc discoveries, the leaders of public health programs throughout the world, and the astute clinicians on the front lines providing life-saving care.
It is up to all of us to ensure we are equipped with the knowledge of how infectious diseases impacts our everyday lives. We’re committed to making this happen. This report outlines some of the major steps we’ve taken to reduce the devastating impact of infectious diseases by empowering the next generation of ID Detectives, investing in research, and advocating for patient care.
The power of our mission begins with YOU! Whether your role is related to research, patient care, advocacy, public health, or philanthropy, we can only realize this vision together. There are many ways you can get involved with the IDSA Foundation and make an impact. Let’s work together to achieve our vision of a world free from the burdens of infectious diseases. On behalf of the IDSA Foundation and the lives we impact daily, thank you for your continued support! Warmest regards, WILLIAM G. POWDERLY, MD, FIDSA IDSA FOUNDATION CHAIR CHRISTOPHER D. BUSKY, CAE CHIEF EXECUTIVE OFFICER IDSA FOUNDATION
3 GIVING SOCIETIES Individual donors like you are uniquely positioned to partner with us by making a significant investment in helping to free the world from infectious diseases that claim over 17 million lives a year. Without the generosity of our donors, we cannot boldly fund strategies that allow for groundbreaking research, develop new and innovative programs and expand those that have proven to inspire brilliant minds in ID. CORPORATE SUPPORTERS The partnerships we attain from corporations worldwide ensure the IDSA Foundation is sustainable and able to provide innovative programs for the future of ID.
Our Corporate Partners have generously funded our ongoing programs or created new funding opportunities for medical students, researchers, and specialists in the field of infectious diseases. LEAVING A LEGACY An important part of life is spending time with our family and friends to decide what we leave this world when we are gone. Many make the choice to leave a legacy for the cause they care about most. If your passion is envisioning a world free from infectious diseases, the IDSA Foundation is here to provide an outlet for you to continue this dream.
The IDSA Foundation is driven by a mission to Build the Future of ID. We are deeply grateful for others who share in this mission, from individuals across the globe, to corporations and foundations standing to make a changed in the world. The support each gives is making it possible to provide research and travel grants to medical students, expand the conversation of ID to patients, caregivers, and parents, and to create innovative approaches to combating the world’s deadliest infectious diseases. Your gift will truly make a difference.We are counting on your support. Visit IDSAFoundation.org today and support the next generation of ID Detectives! WAYS TO SUPPORT DONATING INVESTMENTS Making a charitable gift from an investment portfolio will help the IDSA Foundation create sustainable programming and truly make an impact worldwide.
There are several options for you to consider when donating stocks, bonds, or other investments.
4 2018 ANNUAL REPORT Dr. Daniel R. Lucey is a senior scholar with the O’Neill Institute for National and Global Health Law. He is also an adjunct professor of Medicine-Infectious Diseases at Georgetown University Medical Center, where he has taught for 17 years about outbreaks, pan- epidemics, and pandemics. Since 2001, he has been involved on the ground with anthrax, smallpox vaccination, SARS (China, Canada), H5N1 avian ﬂu (Thailand, Vietnam, Indonesia, Egypt), pandemic ﬂu (USA, Egypt), MERS (Middle East, Korea), Ebola (Sierra Leone, Liberia with MSF at ELWA- 3), Zika (Brazil, USA), yellow fever (Kinshasa, Beijing), chikungunya (Karachi, Islamabad), H7N9 (China), and plague (Madagascar).
Dr. Lucey received his training and MPH at Harvard University (1985–1988) after his medical residency at UCSF and San Francisco General Hospitals and receiving undergraduate and medical degrees at Dartmouth College. He served as an attending physician in infectious diseases in San Antonio, Texas, and at the National Institutes of Health, and as ID chief at the 900-bed Washington Hospital Center in Washington, DC, from 1998–2002 during 9/11 and anthrax scare of 2011.
Q: WHAT DREW YOU TO THE FIELD OF INFECTIOUS DISEASES? DR. LUCEY: I did my residency in San Francisco. It was 1982, and the beginning of the recognition of the AIDS epidemic. I was going to go into neurology, but within two or three months there, I completely converted to infectious disease, largely because of the AIDS epidemic. At the time, we didn’t know the cause. The HIV virus wasn’t discovered until 1983. Q: WHAT HAS BEEN THE BIGGEST CHANGE IN THE PROFESSION? DR. LUCEY: One of the big milestones has been the attention on raising global concern that we’re not prepared to handle pandemics — especially something more deadly than a new “Disease X or Y” more deadly than the 2009-2010 influenza pandemic.
Q: YOU BROUGHT AN IDEA TO THE SMITHSONIAN FOR AN EXHIBIT ON EPIDEMICS. WHAT WAS THE GENESIS OF THAT PROJECT? DR. LUCEY: The idea came to me in 2003 after traveling to Hong Kong, Guangzhou, and Toronto for the severe acute respiratory (SARS) epidemic. SARS is still the best example of what can happen on any day: a brand-new virus transmitted through the air that causes a high degree of illness and death. In just over a few weeks, SARS travelled to 30 countries around the world. As serendipity would have it, in 2014 one of my graduate students at Georgetown knew someone at the Smithsonian National Museum of Natural History who has oversight for new exhibits.
I met with them and proposed an exhibit on multiple outbreaks including SARS, Ebola, HIV, and inﬂuenza. The exhibit was timely because we were approaching the 100-year commemoration of the 1918 pandemic. Q: WHY IS THERE A NEED FOR THIS EXHIBIT? DR. LUCEY: The exhibit is intended to decrease the harmful excessive fear of epidemics. For example, if you look at the the United States reaction to the Ebola epidemic of 2014 in contrast with the actual DR. DANIEL LUCEY, MD, MPH, FIDSA INFECTIOUS DISEASES DETECTIVE, PROFESSOR, AND MENTOR “WHAT’S NEXT IS ALREADY HERE.
WE JUST HAVEN’T RECOGNIZED IT YET.” DR. DANIEL LUCEY ONE KEY TO STOPPING EPIDEMICS IS TO RECOGNIZE “WHAT’S NEXT.”
5 epidemic in West Africa, our fear was far out of proportion to the actual danger. An important part of addressing that fear is global response. At the end of the exhibit, there is a large visual that says, “What’s next?” That’s what matters most. Unbeknownst to me, they included a quote from me: “What’s next is already here. We just haven’t recognized it yet.” That’s the core of my philosophy about epidemics. Note: The exhibit debuted in May 2018 and will remain open until 2021.
Q: CAN YOU SHARE MORE INSIGHTS ON THE VALUE OF THIS EXHIBIT TO THE PUBLIC? DR. LUCEY: The public should be better informed about the realities of epidemics – many of which start in other countries. There is excessive fear about epidemics overseas. Fear is normal, and it’s appropriate. If there’s no fear, there’s no epidemic — and if I don’t feel fear when I go to an epidemic, I shouldn’t be there. Q: WHAT ARE SOME PRACTICAL WAYS THAT WE CAN GLOBALLY ANTICIPATE, RECOGNIZE, AND ACT? IS GLOBAL RESPONSIVENESS PART OF THE EXHIBIT?
DR. LUCEY: The exhibit includes an interactive display panel where visitors can explore the Program for Monitoring Emerging Diseases, ProMED.
Every day for the past 25 years, anyone in the world can send information to ProMED. It can be a newspaper report from Nigeria, China, Brazil, or news from the World Health Organization. ProMED’s team reviews everything that comes in and posts selected information online. With 81,000 subscribers, ProMED gets the news out about what’s out there now, what’s next, and what we need to prepare for, which allows us to respond more effectively and faster than ever before. Q: THROUGHOUT YOUR CAREER, YOU’VE MENTORED MANY COLLEAGUES. WHAT LED YOU TO GET INVOLVED WITH MENTORING? DR. LUCEY: I received wonderful mentoring as a medical student at Dartmouth and in Soweto, South Africa 1979 and 1982, and in San Francisco and Boston.
Receiving mentoring during that time was incredibly formative in my career choice and pathway.
Q: WHAT IS YOUR PERSPECTIVE ON THE MENTORING RELATIONSHIP? DR. LUCEY: When I ﬁnished formal training, I started passing on what I had learned – not just speciﬁc facts, but a way of thinking, an algorithm for the care of patients across the spectrum of well-known to unknown diseases. Importantly, in the process of mentoring younger colleagues we also can learn, both in the USA and internationally. Q: WHAT IS THE SINGLE BIGGEST AREA OF OPPORTUNITY IN THE FIELD OF INFECTIOUS DISEASE? DR. LUCEY: The biggest opportunity is the spectrum of opportunities. You can do clinical care, laboratory research, clinical research, infection prevention and control, regulatory work, military work, and public health service.
As an ID Detective, you can literally travel the world responding to epidemics, furthering the reach of ID knowledge and educating the public. Writing a paper or giving a talk is important, but it’s not enough. We must take action to ﬁght epidemics, including inﬂuencing policy, to prepare and respond better. Then always anticipate, “what’s next?” DR. LUCEY WITH HIS SONS ALEX (L) AND ABE (R) AT THE OPENING OF THE SMITHSONIAN EXHIBIT. “ONE OF THE BIG MILESTONES HAS BEEN RAISING GLOBAL CONCERN THAT WE’RE NOT PREPARED TO HANDLE PANDEMICS...” DR. DANIEL LUCEY
NOTHING HAS SUCH POWER TO BROADEN THE MIND AS THE ABILITY TO INVESTIGATE SYSTEMATICALLY AND TRULY ALL THAT COMES UNDER THY OBSERVATION IN LIFE. MARCUS AURELIUS
7 300 Medical Students and Residents Mentored through our IDWeek Mentorship Program MORE THAN The IDSA Foundation is dedicated to ensuring the availability of funds necessary for the full exploration of all the scientific possibilities that infectious diseases research is generating. WE COULDN’T DO THIS WITHOUT YOU! HERE’S HOW YOUR INVESTMENT HAS HELPED THE NEXT GENERATION OF ID DETECTIVES! 50 Foundation Medical Scholar Awards MORE THAN 1M Towards ID research MORE THAN 12M The IDSA Foundation launched its first Public Awareness Campaign on Flu Awareness with more than VIEWS 45 HIVMA Medical Student Grants BUILDING THE FUTURE OF ID THE IDSA FOUNDATION’S IMPACT IN 2018 90M 2 HIVMA Clinical Fellowships awarded The IDSA Foundation launched its Women of ID campaign highlighting four phenomenal Women of ID who have made a profound impact on the field of ID.
80 Travel Awards
The US Food and Drug Administration and the Centers for Disease Control and Prevention continue to monitor an increase in cases of acute flaccid myelitis that sprang up across the United States. As of December 14, 2018 165 cases ofAFM have been confirmed in 36 states. SOURCE: U.S. FOOD AND DRUG ADMINISTRATION In 2018, South Africa continued to battle the nation’s largest listeria outbreak which sickened 1,600 people and claimed the lives of 216 individuals.The outbreak, which was linked to ready-to-eat sausage products, was resolved in June 2018.
SOURCE: WORLD HEALTH ORGANIZATION A cholera outbreak in Zimbabwe, which began in September, led the Ministry of Health to declare a state of emergency.The most recent case counts include 8340 infections and 50 deaths. SOURCE: WORLD HEALTH ORGANIZATION Health officials in 28 US states continue to investigate an E coli outbreak linked to ground beef, which sickened more than 330 people and led to a recall of more than 12 million pounds of ground beef as of December 12, 2018. SOURCE: WORLD HEALTH ORGANIZATION Acute Flaccid Myelitis Listeria Cholera E coli 9 8 7 6 8 2018 ANNUAL REPORT ID Detectives Were On the Case! 2018 TOP 9 INFECTIOUS DISEASE OUTBREAKS
9 AND THE TOP OUTBREAK OF THE YEAR? Between May and July, 511 individuals were sickened with Cyclospora in 16 states.The traceback investigation linked the outbreak to Fresh Express Salads sold at fast food establishments. SOURCE: WORLD HEALTH ORGANIZATION Hepatitis A outbreaks ran rampant in the United States this year. Fourteen states are currently experiencing outbreaks with Kentucky reporting the most infections with more than 3000 cases. SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION Ebola reappeared in the Democratic Republic of Congo in August, primarily impacting individuals in the North Kivu Province.
More than 500 cases have been confirmed, making this the second largest Ebola outbreak in world history.
SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION The European Center for Disease Prevention and Control continues to track measles cases throughout the European Union and European Economic Area.A total of 9189 cases of infection have been confirmed so far, with Greece, France, and Italy reporting the highest number of cases. SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION A large E coli outbreak linked to romaine lettuce remains under investigation by US and Canadian health agencies.The outbreak was first announced in November,when the US Centers for Disease Control and Prevention advised allAmericans to avoid eating any romaine.The initial outbreak investigation has identified a Santa Barbara,California,farm as one source of the outbreak,but investigators expect more sources to be identified.
The latest case counts from the CDC include 59 cases across 23 US states.
SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION Cyclospora Hepatitis A Ebola Measles E coli 5 2 1 3 4
10 2018 ANNUAL REPORT After earning undergraduate, medical and doctoral degrees at some of the most prestigious universities in the world, doing postdoctoral research with a Nobel Laureate, directing a major lab at the Centers for Disease Control and Prevention (CDC), and then going on to run a successful medical publishing business for more than 40 years, many people would spend their well-earned retirement relaxing. Instead, when Dr. Leslie Norins and his wife, Rainey moved to Florida, a state known for its high population of residents 65 and older, Dr.
Norins felt compelled to become better informed about a disease that not only impacted many members of his new community, but also claimed Rainey’s mother and grandmother: Alzheimer’s Disease (AD). As Dr. Norins delved deeper into the medical literature about AD, he began to notice a striking number of similarities between elements of Alzheimer’s research and those of infectious diseases. Could it be possible that an infectious agent could be a root cause of AD? We spoke with Dr. Leslie and Rainey Norins about how this hypothesis led him to publish a white paper calling for the elevation of Alzheimer’s research to “the highest priority of emergency microbiological search,” and the couple’s subsequent establishment of the Alzheimer’s Germ Quest.
Q: WHAT IS YOUR ELEVATOR PITCH ABOUT WHAT YOU DO AND WHERE YOUR FOCUS IS? DR. NORINS: When Rainey and I moved to Florida, joining a community with a high retiree population, I began to hear more and more about AD. It was a disease that Rainey already had personal experience with, watching ﬁrst her grandmother, then her mother die of the disease. Back when I was in medical school in the early 1960s, the only thing we were taught about the suspected cause of AD was amyloid plaques. Since that time and despite the huge sums of money being poured into Alzheimer’s research grants, there has been very little progress in understanding the disease and littler still that’s helpful to patients.
I ﬁgured that I surely wasn’t the only one struck by the similarities between AD and infectious diseases, yet the more I looked for research on what seemed to me to be obvious similarities between the two conditions, I was shocked to ﬁnd hardly any published papers exploring this angle. I thought maybe at some point research into antibiotics or antiviral drugs had been tried and had been shown ineffective, but it turns out that neither had been tried. By and large, except for a few pioneers, hardly any research had been dedicated to my hypothesis.
I decided to write a white paper making the case for the fact that, based on my two-year intensive review of the scientiﬁc literature, I believe it’s now clear that just one germ—identity not yet speciﬁed, and possibly not yet discovered—is the root cause of most AD. I used the umbrella term “germ” so as to not exclude any possibility, such as bacterium, virus, fungus, parasite, prion, or something new, and referred to it in that white paper as the “Alzheimer’s Germ.” Q: WE’VE BEEN TOLD THAT YOU ARE A VALUED SUPPORTER OF THE IDSA FOUNDATION AND THAT YOU HAVE A LOVE FOR RESEARCH. CAN YOU SHARE WHY YOU CHOSE THE IDSA FOUNDATION FOR RESEARCH GRANT SUPPORT?
DR. NORINS: The ﬁeld of immunology is very intertwined with ID—most ID specialists have grounding in “WHAT BEGAN AS A SIMPLE REVIEW OF THE MEDICAL LITERATURE YIELDED WHAT I FOUND TO BE A SURPRISING NUMBER OF SIMILARITIES BETWEEN AD AND INFECTIOUS DISEASES” DR. LESLIE NORINS DR. LESLIE C. NORINS, MD, PHD, FIDSA AND MRS. ANN “RAINEY” NORINS VISIONARY, PHILANTHROPIST, AND INFECTIOUS DISEASES DETECTIVE TRUE PIONEERS IN RESEARCH
11 immunology. I earned a PhD from the University of Melbourne, where I studied immunology with Sir Macfarlane Burnet, Nobel Laureate.
That experience ﬁrst exposed me to the tie between immunology and ID. I also directed the Venereal Disease Research Laboratory at the CDC, then took a 40-year detour into medical publishing. A few years ago, I connected with the head of AD research at Johns Hopkins and mentioned my interest in the tie between AD and ID; that led to an introduction to their head of ID, who happened to be Dr. Paul Auwaerter, ISDA’s president at the time. As if that wasn’t serendipitous enough, ISDA’s president elect also happened to be Paul’s colleague, and the result of that chance encounter at Hopkins was IDSA sponsoring two grants of $50,000 each.
Q: MRS. NORINS, AD HAS IMPACTED YOU PERSONALLY. WOULD YOU CARE TO ELABORATE ON YOUR JOURNEY WITH AD? MRS. NORINS: AD has had a profound impact on my own life; as Leslie mentioned, I lost both my grandmother and my mother to AD. In addition to losing close family members to the disease, almost every close friend of mine is currently dealing with a family member suffering from the disease. So not only has AD had a profound impact on me personally, I think that overall it’s critically important to humanity because AD can impact everyone. Q: UNDERSTANDING YOUR PASSION FOR ADVANCING AD RESEARCH, CAN YOU TALK A BIT MORE ABOUT YOUR ROLE WITH ALZHEIMER’S GERM QUEST? MRS.
NORINS: Leslie and I have been together since the 1990s, both in life and in business. I had been in business for myself and Leslie was starting a medical publishing business. Since then, we have always worked and traveled together—our ofﬁces are even right next to each other at home.
This endeavor is a labor of love and I’m grateful not only for the continued opportunity for us to work together, but also because AD research has such a personal meaning for me. With my family history, it’s likely that at some point I’ll be facing AD. My hope is that AD is eradicated by the time my kids and grandkids ever have to face the pain and suffering it causes everyone that it impacts. Q: DO YOU THINK WE ARE CLOSE TO IDENTIFYING AN INFECTIOUS AGENT THAT IS THE ROOT CAUSE OF ALZHEIMER’S DISEASE?
DR. NORINS: There are currently about seven plausible candidates, but they haven’t been thoroughly investigated.
There may also be undiscovered agents. I like to say “we have persons of interest but not enough for a formal indictment yet, much less an arrest and conviction.” Rainey adds to this, “It might not even be a single suspect, it might be a gang.” Q: IS THERE ANYTHING ADDITIONAL YOU’D LIKE TO SHARE ON PHILANTHROPY, RESEARCH OR YOUR RELATIONSHIP WITH THE IDSA FOUNDATION?
DR. NORINS: As I’ve become engaged with the IDSA Foundation and have been attending IDSA events, I’ve been fortunate to meet ID professionals worldwide who share my belief in the link between AD and ID. Many of these pioneers—or “converts”—who have also been studying the germ/AD link conﬁrmed my suspicion that only a minimal amount of grant funding has been available to pursue this important line of research. My hope is that if the increased funding for ID/AD research does show a link between the two, a similar public outcry and demand for a cure will spark additional recognition of the importance of ID as it relates to the demand for a cure to AD.
AD/ID research may be the dawn of a new era of ﬁnding links between and potential cures for other diseases. That would truly be an important new frontier for ID specialists. “AD/ID RESEARCH MAY BE THE DAWN OF A NEW ERA OF FINDING LINKS BETWEEN AND POTENTIALLY CURES FOR OTHER DISEASES.” DR. LESLIE NORINS
THE MEANING OF LIFE IS TO FIND YOUR GIFT. THE PURPOSE OF LIFE IS TO GIVE IT AWAY. PABLO PICASSO
13 The IDSA Foundation is driven by a mission to Build the Future of Infectious Diseases. By investing in the brilliant minds of the ID professionals of tomorrow, along with our efforts to expand the reach of the clinicians who work daily to provide life-saving care, together we will reduce the impact of infectious diseases! We know by increasing the number of well-trained ID professionals for tomorrow, we are ENSURING there will be enough ID specialists equipped to take on the next infectious disease threat.
The 2018 financial overview of the IDSA Foundation is presented here. The charts present revenue and expenses for the Foundation and may not be consistent with financial statements, which must be based on generally accepted accounting principles (GAAP).
2018 REVENUES $1,602,706 2018 EXPENSES $1,602,706 IDSA $370,613 Education $400,828 Grant Income $968,790 Career Development $791,736 Individual Income $259,725 Fundraising $249,195 Interest $3,578 Interest $3,578 2018 FINANCIAL INFORMATION Interest $3,578 Interest $3,578 These are unaudited figures.
14 2018 ANNUAL REPORT Lilian M.Abbo, MD Oluwatoyin Adeyemi, MD Lem Aigbivbalu, MD Thamer Alenazi, MD Ogechika K.Alozie, MD, MPH Bishr Al-Ujayli, MD David Andes, MD, FIDSA Michael P. Angarone, DO Robert Arbeit, MD, FIDSA Cesar A.Arias, MD, PHD Michael S.Ashton, MD Hilary M.
Babcock, MD, MPH David A. Balling, MD, FIDSA Brent Barber, MD Donna L. Barrera Jason Barreto, PharmD John Bartlett, MD, FIDSA Anusha Belani, MD Aldith Bellonie-Bespole Debra Benator, MD, FIDSA Luiz Bermudez, MD Constance A. Benson, MD MaryT. Bessesen, MD Nikhil K. Bhayani, MD Thomas Bleck, MD, FIDSA Douglas D. Blevins, MD Emily A. Blumberg, MD John M. Boggs, MD Robert Bonomo, MD, FIDSA Carol L. Brosgart, MD Martha Buitrago, MD Steven D. Burdette, MD Michael Butera, MD, FIDSA Jay C. Butler, MD Richard G. Byrd, MD Michael S. Calderwood, MD, MPH David P. Calfee, MD, MS J.William Campbell, MD Julio Cardenas, MD, FIDSA Christopher F.
Carpenter, MD, MHA Karen C. Carroll, MD Jane Cecil, MD Carlos Cervera, MD Bruce N. Chamovitz, MD MichaelT. Charney, MD Chester Choi, MD Kulkanya Chokephaibulkit, MD Hanumara R. Chowdri, MD Susan Coffin, MD, MPH, FIDSA Keith Collins, MD Miguel Colon-Perez, MD, FIDSA Daria Colombo &Tobias M. Hohl Sara E. Cosgrove, MD, MS Mark A. Crislip, MD Alan Cross, MD, FIDSA Frederick A. Cruickshank, MD Judith Currier, MD, MSC, FIDSA Susan Cu-Uvin, MD Joseph Dalovisio, MD, FIDSA David S. Davenport, MD Margaret de St Aubin Del DeHart, MD, FIDSA Alberto Dolara, MD John Douglas, MD Marylene J. Duah, MD Jeffrey Duchin, MD, FIDSA Robert A.
Duncan, MD, MPH Michael Durkin, MD, MPH Nnaemeka Egwuatu, MD Wilfred Ellis, MD Janet A. Englund, MD Monica Farley, MD, FIDSA Farhan Fazal, MD Judith Feinberg, MD, FIDSA Julio E. Figueroa, MD Mark Finch, MD Neil Fishman, MD, FIDSA Michael Fitzgibbons, MD Henry Fraimow, MD Joseph J. Gadbaw, MD Alison Galdys, MD Joel Gallant, MD, MPH, FIDSA William Gardner, MD, MACP David Gilbert, MD, FIDSA Peter A. Gross, MD Ashley Haase, MD, FIDSA Dafer Haddadin, MD John H. Hammer, MD W. David Hardy, MD Chawki Harfouch Barry J. Hartman, MD Dial Hewlett, MD, FIDSA Claudia Hildreth Martin S. Hirsch, MD John L.
Ho, MD Tobias M. Hohl, MD, PhD David C. Hooper, MD Thomas M. Hooton, MD Michael Horberg, MD, FIDSA Michael K. Hori, MD James M. Horton, MD Stephen W. Hosea, MD Alexander Huang, MS Nicole Iovine, MD, PhD, FIDSA Michael G. Ison, MD, MS, FIDSA Eric Jacobson, MD, PhD, FIDSA Mamta K. Jain, MD Chandy John, MD Patrick Joseph, MD, FIDSA Manisha Juthani-Mehta, MD, FIDSA Mohammad Kabbesh, MD Elizabeth Kailath, MD Samuel Katz, MD, FIDSA Carol A. Kauffman, MD Erica E. Kaufman West, MD Carol A. Kemper, MD Hyun Kyun Ki Peter H. Kilmarx, MD Shirley Klein, MD Corinne Klein, MD Palaniandy K. Kogulan, MD Susan Koletar, MD, FIDSA Tsun Sheng Ku Jennie Kwon, DO, MS Katherine Laessig, MD Maryrose R.
Laguio-Vila, MD Ebbing Lautenbach, MD, MPH, MS, FIDSA Edward E. Leonard, MD Donald P. Levine, MD Alvaro Lopez, MD Eddie Louie, MD Jeffery S. Loutit, MD Daniel Lucey, MD, MPH, FIDSA Sheila Lukehart, PhD, FIDSA Tammy S. Lundstrom, MD Ruth Lynfield, MD Ricardo Maldonado, MD Farrin A. Manian, MD Kendall Marcus, MD Edgar Marcuse, MD, MPH, FIDSA Harold S. Margolis, MD, FIDSA Aileen M. Marty, MD Wilbert H. Mason, MD David A. Mayorga, MD Dana Mazo, MD J. Ian McMillen, MD Andre G. Melendez, MD, MSC MichaelT. Melia, MD Brian S. Metzger, MD, MPH Eric Milefchik, MD Daniel Morgan, MD, FIDSA Andrew Morris, MD DarilynV.
Moyer, MD Kathleen M. Mullane, DO, PharmD Sheila Murphey, MD Daniel M. Musher, MD Martin and Beverly Myers, MD, FIDSA Patrick Njoku, MD Obiefuna Okoye, MD Sean OLeary, MD, MPH Margaret Olsen, MPH, PhD Catherine O’Neal, MD Jacob Oommen, MD Luis Ostrosky-Zeichner, MD, FIDSA Tara N. Palmore, MD Demosthenes Pappagianis, MD, PHD Kathleen Paranada Steven W. Parker, MD AndrewT. Pavia, MD Stephen I. Pelton, MD Rosalie Pepe, MD Trish M. Perl, MD, MSC $100-$499 WE ARE GRATEFUL TO OUR DONORS WHO ARE INVESTING IN THE NEXT GENERATION OF ID DETECTIVES 2018 DONORS
15 Anna K. Person, MD Eskild A. Petersen, DMsc, DTM&H, MBA, MD AnnKatrin Peterson Jappelli, MD, MSC Eva Piessens, MD Andrea Polesky, MD Richard Pollard, MD Paul S. Pottinger, MD Harold S. Raucher, MD Susan Ray, MD, FIDSA Ricardo R. Reyes, MD Frank S. Rhame, MD Gunter K. Rieg, MD Noah Robbins, MD Elizabeth Robilotti, MD, MPH Patrick Robinson, MD, FIDSA Leon Robison, MD Clare Rock, MD, MS Harry Rosado-Santos, MD Anne Rowley, MD J. Kenyon Rupnik Edward Ryan, MD, FIDSA George Sakoulas, MD Jorge L. Santana Bagur, MD Mary Schmidt, MD, MPH, FIDSA Steven M. Schnittman, MD Robert Schooley, MD, FIDSA Jennifer Schranz, MD John C.
Schwab Steven Schwimmer, DO Lucyann M. Sciandra, DO Juan C. Sepulveda Arias, MD, PHD Dennis M. Shoemaker DO Upinder Singh, MD Thomas G. Slama, MD Dorothy Slavin, MD James Smith, MD Jeffrey Snedeker, MD Graham M. Snyder, MD, MS Stephen Sokalski, DO, FIDSA April Soto, MD Paul M. Southern, MD Stanley M. Spinola, MD Joanne Stekler, MD, MPH, FIDSA Dennis L. Stevens, MD Dennis Sula, MD, MD, FIDSA Vidya Sundareshan Ronaldo B. Supena, MD Martha H.Tanner, MD, FIDSA JoaoTavares, MD PatrickTennican, MD RobertThompson, MD Maureen R.Tierney-Brennan, MD, MSC BhatrapholTingpej, MD GreggTolliver, MD, MPH TownsonTsai, MD TrevorVan Schooneveld, MD MaryVogler, MD, FIDSA Kathleen Wairimu, MD Richard Watkins, MD, MS, FIDSA Scott Weisenberg, DTM&H, MD, MSC Charles S Weiss, MD, MPH Thomas Wellems, MD, PhD Soe S.Win, MBBS Dean L.Winslow, MD Mallory D.Witt, MD Laila E.Woc-Colburn, MD MichaelT.Wong, MD Deborah S.Yokoe, MD, MPH Clarence Young, MD, FIDSA Vincent B.Young, MD, PHD HeatherYun, MD, FIDSA Judith Aberg, MD, FIDSA Wendy Armstrong, MD, FIDSA Barbara A.Atkinson, DO, FIDSA Carol Baker, MD, FIDSA Johan Bakken, MD, PhD, FIDSA Ellen Jo Baron, PhD, FIDSA Nesli Basgoz, MD, FIDSA Frank Berkowitz, MD, MPH Susan Boruchoff, MD, FIDSA, FSHEA Dale W.
Bratzler, DO, MPH, FIDSA R. Michael Buckley, MD, FIDSA Angela M. Caliendo, MD, PHD, FIDSA Henry Chambers, MD, FIDSA James Cherry, MD, FIDSA James Cutrell, MD Cornelia L. Dekker, MD, FIDSA Carlos Del Rio, MD, FIDSA Alfred DeMaria, MD, FIDSA, FSHEA Joan L. Drucker, MD David Drutz, MD, FIDSA Michael W. Dunne, MD Simintha Esson, MA Thomas File, MD, FIDSA David N. Fredricks, MD, FIDSA Anne Gershon, MD, FIDSA Jeannette Guarner, MD, FIDSA Cathy Hardalo, MD Mary Hayden, MD, FIDSA, FSHEA David Hong, MD Eric R. Houpt, MD, FIDSA James Hughes, MD, FIDSA Bach & Godofsky ID Ravi Jhaveri, MD, FIDSA Robert Kaplan, MD Wendy Keitel, MD, FIDSA Mark Keroack, MD Keith P.
Klugman, MD, FIDSA Oliver Liesenfeld, MD Jeanne M. Marrazzo, MD, FIDSA Celia J. Maxwell, MD, FIDSA Daniel P. McQuillen, MD, FIDSA Thomas Moore, MD, FIDSA Barbara Murray, MD, FIDSA Susanna Naggie, MD, FIDSA Ronald Nahass, MD, FIDSA, FSHEA Ronald Lee Nichols, MD, FIDSA Josh Nosanchuk, MD, FIDSA Ighovwerha Ofotokun, MD, FIDSA George Pankey, MD, FIDSA Jan Patterson, MD, FIDSA, FSHEA Thomas Patterson, MD, FIDSA Georges Peter, MD, FIDSA Larry K. Pickering, MD, FIDSA Liise-anne Pirofski, MD, FIDSA Donald Poretz, MD, FIDSA Bill Powderly, MD, FIDSA Susan Rehm, MD, FIDSA Alice Savage, MD, PhD Steven Schmitt, MD, FIDSA John Scott, MD, FIDSA Cynthia Sears, MD, FIDSA Spencer Seufert John Sherris, MD, FIDSA Steven Sperber, MD, FIDSA Kent Stock, DO, MBA MarvinTenenbaum, MD, FIDSA David LeeThomas, MD, FIDSA Allen Tunkel, MD, FIDSA Richard Whitley, MD, FIDSA Paul Auwaerter, MD, MBA, FIDSA Helen Boucher, MD, FIDSA Chris Busky, CAE Thomas Fekete, MD, FIDSA Mary Jane Ferrero, PhD, FIDSA Eliot Godofsky, MD, FIDSA Lucy StuartTompkins, MD, PHD, FIDSA, FSHEA ALK Alheimer’s Germ Quest, Inc.
Gilead Sciences, Inc.
Janssen Pharmaceutical Company Pfizer Pharmaceutical Company ViiV Healthcare $500-$4,999 $5,000 + Organizational Donors
William G. Powderly, MD, FIDSA  Chair Washington University School of Medicine Thomas Fekete, MD, FIDSA  Vice Chair Temple University Medical School Helen W. Boucher, MD, FIDSA  Secretary/Treasurer Tufts Medical Center Eliot W. Godofsky MD, FIDSA  Development Committee Chair Bach & Godofsky Russel Petrak MD, FIDSA  Metro Infectious Disease Consultants Johan S. Bakken, MD, PhD, FIDSA  (Retired) St. Luke’s ID Associates Barbara E.
Murray, MD, FIDSA  University of Texas Health Science Center Chris Busky, CAE Chief Executive Officer Arthinia Morgan, MBA Senior Fundraising Manager Katie Bourgoin Office Assistant BOARD OF DIRECTORS IDSA FOUNDATION STAFF 16 2018 ANNUAL REPORT
THE INFECTIOUS DISEASES SOCIETY OF AMERICA FOUNDATION IS THE PREMIER RESOURCE IN EDUCATING THE PUBLIC ON INFECTIOUS DISEASES, BUT IT’S OUR SUPPORTERS WHO FUEL THIS CRITICAL WORK. THANK YOU!
1300 WILSON BOULEVARD, SUITE 300 ARLINGTON,VIRGINIA 22209 703-299-0200 WWW.IDSAFOUNDATION.ORG FOUNDATION@IDSOCIETY.ORG